216 related articles for article (PubMed ID: 21143501)
1. Influence of different degrees of liver impairment on the pharmacokinetics of clazosentan.
Bruderer S; Detishin V; Tsvitbaum N; Dingemanse J
Br J Clin Pharmacol; 2011 Jan; 71(1):52-60. PubMed ID: 21143501
[TBL] [Abstract][Full Text] [Related]
2. Influence of severe renal impairment on the pharmacokinetics of clazosentan.
Bruderer S; Sasu B; Tsvitbaum N; Dingemanse J
J Clin Pharmacol; 2011 Mar; 51(3):413-21. PubMed ID: 20926750
[TBL] [Abstract][Full Text] [Related]
3. Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist.
van Giersbergen PL; Dingemanse J
Eur J Clin Pharmacol; 2007 Feb; 63(2):151-8. PubMed ID: 16636870
[TBL] [Abstract][Full Text] [Related]
4. Effect of gender on the tolerability, safety and pharmacokinetics of clazosentan following long-term infusion.
van Giersbergen PL; Dingemanse J
Clin Drug Investig; 2007; 27(11):797-802. PubMed ID: 17914898
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo pharmacokinetic characteristics of clazosentan, an intravenous endothelin receptor antagonist, in humans.
van Giersbergen PL; Treiber A; Dingemanse J
Int J Clin Pharmacol Ther; 2009 Mar; 47(3):169-77. PubMed ID: 19281726
[TBL] [Abstract][Full Text] [Related]
6. Influence of ethnic origin and sex on the pharmacokinetics of clazosentan.
van Giersbergen PL; Gunawardena KA; Dingemanse J
J Clin Pharmacol; 2007 Nov; 47(11):1374-80. PubMed ID: 17906281
[TBL] [Abstract][Full Text] [Related]
7. PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT.
Henrich A; Juif PE; Dingemanse J; Krause A
J Pharmacokinet Pharmacodyn; 2021 Apr; 48(2):213-224. PubMed ID: 33389549
[TBL] [Abstract][Full Text] [Related]
8. Target-Mediated Population Pharmacokinetic Modeling of Endothelin Receptor Antagonists.
Volz AK; Dingemanse J; Krause A; Lehr T
Pharm Res; 2019 Dec; 37(1):2. PubMed ID: 31823033
[TBL] [Abstract][Full Text] [Related]
9. Challenges in collecting pharmacokinetic and pharmacodynamic information in an intensive care setting: PK/PD modelling of clazosentan in patients with aneurysmal subarachnoid haemorrhage.
Zisowsky J; Fuseau E; Bruderer S; Krause A; Dingemanse J
Eur J Clin Pharmacol; 2014 Apr; 70(4):409-19. PubMed ID: 24458541
[TBL] [Abstract][Full Text] [Related]
10. Preventive Effect of Clazosentan against Cerebral Vasospasm after Clipping Surgery for Aneurysmal Subarachnoid Hemorrhage in Japanese and Korean Patients.
Fujimura M; Joo JY; Kim JS; Hatta M; Yokoyama Y; Tominaga T
Cerebrovasc Dis; 2017; 44(1-2):59-67. PubMed ID: 28463833
[TBL] [Abstract][Full Text] [Related]
11. Influence of Rifampin-Mediated Organic Anion-Transporting Polypeptide 1B1/1B3 Inhibition on the Pharmacokinetics of Clazosentan.
Juif PE; Voors-Pette C; Ufer M; Dogterom P; Dingemanse J
Clin Transl Sci; 2019 Sep; 12(5):440-444. PubMed ID: 31004470
[TBL] [Abstract][Full Text] [Related]
12. Association Between Vomiting and QT Hysteresis: Data from a TQT Study with the Endothelin A Receptor Antagonist Clazosentan.
Juif PE; Dingemanse J; Voors-Pette C; Ufer M
AAPS J; 2020 Aug; 22(5):103. PubMed ID: 32748293
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling.
Macdonald RL; Higashida RT; Keller E; Mayer SA; Molyneux A; Raabe A; Vajkoczy P; Wanke I; Bach D; Frey A; Nowbakht P; Roux S; Kassell N
Stroke; 2012 Jun; 43(6):1463-9. PubMed ID: 22403047
[TBL] [Abstract][Full Text] [Related]
14. Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist.
Berger B; Dingemanse J; Sabattini G; Delahaye S; Duthaler U; Muehlan C; Krähenbühl S
Clin Pharmacokinet; 2021 Oct; 60(10):1349-1360. PubMed ID: 34002356
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.
Narasimhan NI; Dorer DJ; Davis J; Turner CD; Marbury TC; Sonnichsen D
Cancer Chemother Pharmacol; 2014 Aug; 74(2):341-8. PubMed ID: 24934866
[TBL] [Abstract][Full Text] [Related]
16. Asenapine pharmacokinetics in hepatic and renal impairment.
Peeters P; Bockbrader H; Spaans E; Dogterom P; Lasseter K; Marbury T; Gibson GL; de Greef R
Clin Pharmacokinet; 2011 Jul; 50(7):471-81. PubMed ID: 21651314
[TBL] [Abstract][Full Text] [Related]
17. Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment.
Fontes MSC; Dingemanse J; Halabi A; Tomaszewska-Kiecana M; Sidharta PN
Sci Rep; 2022 Nov; 12(1):19067. PubMed ID: 36352054
[TBL] [Abstract][Full Text] [Related]
18. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study.
Vajkoczy P; Meyer B; Weidauer S; Raabe A; Thome C; Ringel F; Breu V; Schmiedek P
J Neurosurg; 2005 Jul; 103(1):9-17. PubMed ID: 16121967
[TBL] [Abstract][Full Text] [Related]
19. Different Doses of Clazosentan for Aneurismal Subarachnoid Hemorrhage: A Meta-Analysis of Randomized Controlled Trials.
Rong WL; Xiao X; Zhao JL; Yang XW; Hu ZL; Li MH
Am J Ther; 2018; 25(6):e652-e660. PubMed ID: 26752653
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.
Roy MJ; Erdman KA; Abeyratne AT; Plumb LC; Lasseter K; Riff DS; Keirns JJ
Clin Pharmacokinet; 2013 May; 52(5):385-95. PubMed ID: 23456393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
